Risk and impact of renal impairment of locally advanced head and neck squamous cell carcinoma patients who received chemoradiotherapy with cisplatin

Patimarattananan, Thana; Pattaranutaporn, Poompis; Unwanatham, Nattawut; Jiarpinitnun, Chuleeporn; Nongnuch, Arkom; Ngamphaiboon, Nuttapong

doi:10.1093/annonc/mdz252.024

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, in clinical practice, patients with locally advanced NPC might be receiving CD of cisplatin as recommended by the standard guideline or pivotal phase III randomized studies [5][6][7][8]. This may lead to unnecessary complications and toxicities, especially from cisplatin [14,15]. Moreover, these complications and toxicities may delay and/or affect radiation treatment, leading to poor survival.…”

Section: Discussionmentioning

confidence: 99%

“…About 13.6% patients with cancer treated with cisplatin develop nephrotoxicity, i.e., acute kidney injury (AKI), which is significantly associated with administrated cisplatin dose [13]. Incidences of nephrotoxicity among head and neck cancer patients receiving cisplatin CRT were 30-34%, higher than in those with other cancer types [14,15]. Therefore, we evaluated the optimal cisplatin CD for definitive CRT that would maintain efficacy and minimize toxicity among patients with nonmetastatic NPC in a multicenter setting in Thailand.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand

et al. 2020

View full text Add to dashboard Cite

Background Chemoradiotherapy (CRT) with high cumulative doses (CDs) of cisplatin has been considered the standard of care for non-metastatic nasopharyngeal carcinoma (NPC). However, given most patients’ inability to tolerate high CDs due to cisplatin-related toxicities, the optimal CD of cisplatin during CRT remains undetermined. Methods Patients with non-metastatic NPC who received CRT with cisplatin between 2007 and 2017 were identified through the Thai head and neck cancer multicenter database and then categorized according to cisplatin CD (mg/m2) received. All complications and cisplatin-related toxicities during CRT were recorded. Results We identified 779 non-metastatic NPC patients receiving low (≤150; n = 97), intermediate (151–250; n = 411), and high (> 250; n = 271) CDs of cisplatin. Low CD patients had significantly lower mean actual radiation dose (p < 0.001) and more radiotherapy delay (p = 0.010), while intermediate CD patients had the least hospitalization (p < 0.001). Overall, 39.3% of the patients experienced cisplatin-related toxicity, which was associated with poor overall survival (OS) (p = 0.001). Acute kidney injury was observed in 7% in all patients, which was highest among low CD patients (15.5%; p = 0.002). Intermediate CD patients had significantly longer median OS than the low and high groups (64 vs. 49.8 vs. 53.2, respectively; p = 0.015). Univariate, but not multivariate, analysis showed that CD of cisplatin was significantly associated with OS. Conclusion CD of cisplatin during CRT was not an independent prognostic factor for OS. An intermediate CD induced minimal toxicity without compromising survival and should be considered the optimal CD. Nonetheless, a randomized phase 3 study evaluating the optimal CD of cisplatin is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand

et al. 2020

View full text Add to dashboard Cite

show abstract

“…About 13.6% patients with cancer treated with cisplatin develop nephrotoxicity, i.e., acute kidney injury (AKI), which is significantly associated with administrated cisplatin dose [13]. Incidences of nephrotoxicity among head and neck cancer patients receiving cisplatin CRT were 30%-34%, higher than in those with other cancer types [14,15]. Therefore, we evaluated the optimal cisplatin CD for definitive CRT that would maintain efficacy and minimize toxicity among patients with locally advanced NPC in a multicenter setting in Thailand.…”

Section: Introductionmentioning

confidence: 99%

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with locally advanced nasopharyngeal carcinoma: a multicenter analysis in Thailand

Ngamphaiboon

Dechaphunkul

Setakornnukul

et al. 2020

Preprint

View full text Add to dashboard Cite

IntroductionChemoradiotherapy (CRT) with high cumulative doses (CDs) of cisplatin has been considered the standard of care for locally advanced nasopharyngeal carcinoma (LA-NPC). However, given most patients’ inability to tolerate high CDs due to cisplatin-related toxicities, the optimal CD of cisplatin during CRT remains undetermined.MethodsPatients with LA-NPC who received CRT with cisplatin between 2007 and 2017 were identified through the Thai head and neck cancer multicenter database and then categorized according to cisplatin CD (mg/m2) received. All complications and cisplatin-related toxicities during CRT were recorded.ResultsWe identified 779 LA-NPC patients receiving low (£150; n=97), intermediate (151–250; n=411), and high (>250; n=271) CDs of cisplatin. Low CD patients had significantly lower mean actual radiation dose (p<0.001) and more radiotherapy delay (p=0.010), while intermediate CD patients had the least hospitalization (p<0.001). Overall, 39.3% of the patients experienced cisplatin-related toxicity, which was associated with poor overall survival (OS) (p=0.001). Acute kidney injury was observed in 7% in all patients, which was highest among low CD patients (15.5%; p=0.002). Intermediate CD patients had significantly longer median OS than the low and high groups (64 vs. 49.8 vs. 53.2, respectively; p=0.015). Univariate, but not multivariate, analysis showed that CD of cisplatin was significantly associated with OS.ConclusionCD of cisplatin during CRT was not an independent prognostic factor for OS. An intermediate CD induced minimal toxicity without compromising survival and should be considered the optimal CD. Nonetheless, a randomized phase 3 study evaluating the optimal CD of cisplatin is warranted.

show abstract

Co-delivery of celastrol and lutein with pH sensitive nano micelles for treating acute kidney injury

Pang

Duan

Zhao

et al. 2022

Toxicology and Applied Pharmacology

View full text Add to dashboard Cite

Risk and impact of renal impairment of locally advanced head and neck squamous cell carcinoma patients who received chemoradiotherapy with cisplatin

Cited by 3 publications

References 0 publications

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with locally advanced nasopharyngeal carcinoma: a multicenter analysis in Thailand

Co-delivery of celastrol and lutein with pH sensitive nano micelles for treating acute kidney injury

Contact Info

Product

Resources

About